viewEmerald Clinics Ltd

Emerald Clinics makes first big move into UK with Spectrum Biomedical deal

Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver an RWE asset focused on the safety and clinical outcomes for cannabis-based medicines produced by SBUK. The contract is valued at up to £400,000 (around A$723,000) with an initial fee of £150,000 for Emerald to start work on the project immediately.

Quick facts: Emerald Clinics Ltd

Price: 0.083 AUD

Market: ASX
Market Cap: $17.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...


Emerald Clinics announce new collaborations to enhance and expand its...

Emerald Clinics Ltd's (ASX:EMD) Dr Michael Winlo speaks to Proactive's Andrew Scott after announcing they've signed new agreements that he says will enhance its data capture technology platform and support the launch of a new digital health and clinical monitoring service called ‘Sentinel...

on 22/6/20

2 min read